ClinicalTrials.gg
Not yet recruitingNCT07722728Updated Jul 23, 2026

A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia

A Phase 2/3 interventional study of 30 mg B2227 and 70 mg B2227 in Schizophrenia, sponsored by Bostal Drug Delivery Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Bostal Drug Delivery Co., Ltd · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Planned enrollment
16th of 23
84 · median 129
Started
2026
with 2 others
Phase 2/3
6 of 23
1 open now
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Bostal Drug Delivery Co., Ltd

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 16th largest by planned enrollment, is one of 3 that started in 2026, is one of 6 in phase 2/3, and was the 23rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The study is to evaluate the pharmacokinetic profile of B2227 Extended-Release Injectable Suspension against Vraylar® Cariprazine capsules of AbbVie Inc. in participants with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant and/or their legally acceptable representative (LAR) must sign an form (ICF) indicating that the participant understands the purpose of and procedures required for the study as described in Section 10.1.3 and in this protocol and is willing to participate in the study.
  2. Male or female participant with age of 18-65 years (both inclusive) at the time of signing the informed consent.
  3. Participant has a (BMI) within the range 18.50 to 30.00 kg/m2 (inclusive).
  4. Participant diagnosed with schizophrenia as per , Fifth Edition, Text Revision (DSM-5-TR) (or later) criteria.
  5. Participant with a Clinical Global Impression-Severity of Illness (CGI-S) Score of ≤ 4 at screening.
  6. Participant with Positive and Negative syndrome-scale (PANSS) total score ≤75 at screening.
  7. Schizophrenic participants who are clinically stable on their current antipsychotic medication other than cariprazine, for a duration of at least 8 weeks prior to screening.

    Note: Participants must NOT be taking > 1 antipsychotic medication for their disease.

  8. Participant who has previously received and tolerated oral cariprazine 3 mg or higher dose (no discontinuations due to AEs attributable to cariprazine).
  9. use by participant or participant's partner(s) should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:

    • Is not a woman of (WOCBP) as defined in Appendix 4: Contraceptive and Barrier Guidance.

    OR

    • Is a WOCBP and agrees to remain on an acceptable contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency when used consistently and correctly, as described in Appendix 4: Contraceptive and Barrier Guidance during the study period and for at least 12 weeks after the last dose of the study intervention. The investigator should evaluate the effectiveness and the potential for contraceptive method failure (e.g., noncompliance, recently initiated) of the contraceptive method in relation to the first dose of the study intervention.
    • A WOCBP agrees not to donate eggs (ova, oocytes), freeze them for future use for reproduction or retrieve them for their own use during the recommended period of contraception. A WOCBP agrees to seek advice about donation and cryopreservation of germ cells.
    • A WOCBP must have a negative highly sensitive pregnancy test (serum) at screening assessment and a negative highly sensitive pregnancy test (urine) on day 1 prior to the first dose of intervention, but no more than 7 days before the first dose of the study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
    • Additional requirements for pregnancy testing during and after study intervention are located in Section 8.3.5.

    The investigator is responsible for reviewing medical history, menstrual history, and recent sexual activity to decrease the risk of inclusion of a woman with early undetected pregnancy.

  10. Male participant is eligible to participate if he agrees to the following during the study period and for at least 12 weeks after the last dose of the study intervention.

    • Must agree not to plan to father a child or donate sperm for reproduction;

    PLUS, EITHER:

    • Be abstinent from heterosexual intercourse as his preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent; OR
    • Must agree to use contraception /barrier as detailed below:
    • A male participant must wear a condom when engaging in any activity that allows for the passage of ejaculate to another person.
    • Male participant should also be advised of the benefit for a female partner(s) to use a highly effective method of contraception as the condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
  11. Participant has adequate hematologic, liver and renal functions at screening assessment.

    a ≥1500 cells/μL b count ≥100000 cells/μL c ≥9.0 g/dL d White blood cell count (WBC) ≥ 4000 cells/μL e ≥ 60 mL/minute (using the Cockcroft-Gault Equation). f (ALT) and aspartate transaminase (AST) ≤ 2 × (ULN) g Total \< 1.2 mg/dL h Alkaline phosphatase ≤ 2 * ULN

  12. Participant willing and able to adhere to the lifestyle restrictions specified in this protocol.
  13. Participant who agrees to avoid drinking alcohol during the study.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a known (≥Grade 3) allergies, , or intolerance to any of the study interventions (or related class of drugs) or components/ thereof [refer to the investigator's brochure (IB)/US-prescribing information (USPI) 1,2], or drug or other allergies that in the opinion of the investigator or medical monitor, contraindicate participation in the study.
  2. Participant has to the use of B2227, cariprazine per local prescribing information.
  3. Participants currently in acute, manic episodes of schizophrenia, as assessed by the Investigator.
  4. Participants with history of or a current (or later) diagnosis of concurrent mental disorder besides schizophrenia (e.g., schizoaffective-disorder, major depressive disorder, bipolar I disorder, bipolar II disorder, general anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, dementia or mild neurocognitive disorder, and personality disorder).
  5. Participants who have attempted suicide within 12 months prior to screening based on history, or who had suicidal ideation within 2 months prior to screening based on C-SSRS (Columbia-Suicide Severity Rating Scale), or who exhibit violent tendencies/behavior, as clinically assessed by the investigator.
  6. Participants with history or presence of neuroleptic malignant syndrome (NMS), tardive dyskinesia, Parkinson's disease, epilepsy or other seizure disorders, cognitive and motor impairment, pathological gambling, dysphagia or other compulsive behavior.
  7. Participants with a prior personal or family history of dystonic reactions to medications.
  8. Participants with clinically significant dyslipidemia as per Investigator's discretion.
  9. Participants with a history of syncope or a presence of significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 20 mm Hg or more and/or a drop in diastolic blood pressure of 10 mm Hg or more within 3 minutes of standing from supine) at screening.
  10. Participants with known history or presence of any uncontrolled systemic disease (e.g., cardiovascular disease, cerebrovascular disease, diabetes mellitus, etc.) as per clinical judgment of clinical investigator.
  11. Participants who are on concurrent treatment with other anti-psychotic Long-acting Injection (LAIs).
  12. Participants who have received concomitant medications that are strong inhibitors or CYP3A4 inducers within 14 days prior to study drug administration (or within five halflives since the last drug administration, whichever is greater), or is expected to require such treatment during the study. Refer Table 6-2.
  13. Participants with any other medical condition or serious inter-current illness that, in the opinion of the Investigator, may make it undesirable for the patient to participate in the study including but not limited to cirrhosis or psychiatric illness other than schizophrenia /social situations that would limit adherence to study requirements.
  14. Any other condition(s) which could significantly interfere with protocol compliance.
  15. Participants found positive for urine screen for drugs of abuse (except for benzodiazepine, which is a permissible medication if supported by prescription).
  16. Participants with major surgical procedure (including periodontal) within 28 days of intervention dosing or plan to have major surgical procedure during the study.
  17. Participants with current surgical or other non-healing wounds.
  18. Participants who have participated in any clinical trial with another investigational drug or other investigational intervention within 90 days of enrolment.
  19. Participant has donated blood or blood product or had substantial Loss of blood ≥ 350 mL (1 unit) within 90 days before enrolment in the study.
  20. Participants with history of difficulty with donating blood or difficulty in accessibility of veins.
  21. Presence of surface antigen (HBsAg) at screening or within 3 months prior to the first dose of investigational intervention.
  22. Positive antibody test result at screening or within 3 months prior to starting the investigational intervention.

    NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative hepatitis C RNA test is obtained.

  23. Has known (HIV) seropositive status, or positive HIV antibody test at screening.
  24. Alcoholics (alcohol consumption of more than 14 units per week for men and more than 7 units per week for women, each unit equivalent to 360 mL of beer or 150 mL of wine or 45 mL of spirits with 40% alcohol content) and those who have a positive urine alcohol test.
  25. Participants who have consumed tobacco-containing products (smoking, tobacco chewing, etc.), xanthine containing food, poppy seeds, and beverages (chocolates, tea, coffee, or cola drinks) or alcohol within 48.00 hours (02 days) prior to dosing.
  26. Participants who have consumed grapefruit or its juice and cranberry juice within 96.00 hours (04 days) prior to dosing.
  27. Participants currently smoking greater than or equal to 10 cigarettes or equivalent per day.
  28. Participant unable to swallow solid, oral dosage forms whole with the aid of water (participants may not chew, divide, dissolve, or crush the investigational intervention).
  29. Participant with a documented medical history or current evidence of uncontrolled, clinically significant intercurrent medical condition(s), therapy, laboratory abnormality, or other circumstance for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    1.5 mg Vraylar®

    Drug: Vraylar® 1.5 mg

  • Experimental
    3.0 mg Vraylar®

    Drug: Vraylar® 3.0 mg

  • Experimental
    4.5 mg Vraylar®

    Drug: Vraylar® 4.5 mg

  • Experimental
    6 mg Vraylar®

    Drug: Vraylar® 6.0 mg

  • Experimental
    B2227 30 mg

    Drug: 30 mg B2227

  • Experimental
    B2227 70 mg

    Drug: 70 mg B2227

  • Experimental
    B2227 150 mg

    Drug: 150 mg B2227

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: Pre-dose to 190 days post-dose

  2. Tmax

    Time frame: Pre-dose to 190 days post-dose

  3. AUC0-last

    Time frame: Pre-dose to 190 days post-dose

  4. AUC0-infinity

    Time frame: Pre-dose to 190 days post-dose

  5. T1/2

    Time frame: Pre-dose to 190 days post-dose

  6. Kel

    Time frame: Pre-dose to 190 days post-dose

  7. Vd/F

    Time frame: Pre-dose to 190 days post-dose

  8. MRT

    Time frame: Pre-dose to 190 days post-dose

  9. AUC_%Extrap_obs

    Time frame: Pre-dose to 190 days post-dose

  10. Cmax,ss

    Time frame: Pre-dose to 57 days post-dose

  11. Cmin,ss

    Time frame: Pre-dose to 57 days post-dose

  12. Cavg,ss

    Time frame: Pre-dose to 57 days post-dose

  13. AUC24h

    Time frame: Pre-dose to 57 days post-dose

  14. Fluctuation

    Time frame: Pre-dose to 57 days post-dose

  15. Swing

    Time frame: Pre-dose to 57 days post-dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 23, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07722728
Lead sponsor
Bostal Drug Delivery Co., Ltd
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 23, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion